- Research article
- Open Access
- Open Peer Review
Modulation of RANTES expression by HCV core protein in liver derived cell lines
© Ruggieri et al; licensee BioMed Central Ltd. 2007
- Received: 16 November 2006
- Accepted: 12 June 2007
- Published: 12 June 2007
Hepatitis C virus (HCV) infection is associated with high percentage of chronicity which implies the ability of the virus to evade or modulate host cell immune system. Modulation of chemokines, such as RANTES may be part of the virus induced pathogenicity. We examined the effect of core and structural proteins of HCV on RANTES expression in two liver derived cell lines, HepG2 and Chang Liver (CHL).
HepG2 and Chang Liver (CHL) cell lines were established and selected for constitutive expression of HCV core and structural genes. Flow cytometry and quantitative RT-PCR analysis were performed to examine the effect of HCV core protein on RANTES expression. Luciferase analysis after RANTES-Luc-promoter transfection of established cell lines was assayed by luminometer measurements (RLU) of RANTES promoter activity. IRF-1 and IRF-7 expression was then examined by immunoblotting analysis.
Results of flow cytometry and RT-PCR analysis indicated that RANTES is differentially regulated by HCV core protein in the two cell lines examined as its expression was inhibited in HepG2 cells, by a reduction of RANTES promoter activity. Conversely, RANTES protein and mRNA were induced by the core protein in CHL cells, through the induction of the promoter.
Since HCV genome modulates IRF-1 and IRF-7 in replicon system and IRF-1, IRF-3 and IRF-7 have been reported to regulate RANTES promoter in various cell systems, analysis of the mechanism underlying RANTES modulation by the core protein revealed that IRF-1 expression was induced in HepG2 cells by the core protein, whereas in CHL cells it was expressed at a very low level that was not influenced by transfection with the core protein construct. This suggested that IRF-1 level may mediate the expression of RANTES in cell lines of liver origin. The effect of the core protein on RANTES promoter was countered by co-transfection with NF90, a double-stranded-RNA binding protein that activates some interferon response genes and acts as a component of cell defense against viral infection.
HCV core protein have opposite effects on the expression of RANTES in different cell types in vitro, possibly reflecting a similar scenario in different microenvironments in vivo.
- Hep39 Cell Line
- Chang Liver Cell
- RANTES Expression
- RANTES Promoter
- Human Hepatoblastoma Cell Line
Hepatitis C virus (HCV) is the major cause of chronic liver disease worldwide associated with the development of hepatocellular carcinoma (HCC), that is the fifth most common cancer worldwide , with increasing incidence in Europe  and the leading cause of death amongst cirrhotic patients [3, 4].
One of the main features of HCV infection is the high percentage of chronicity which implies the ability of the virus to evade or modulate host cell immune system. Initial inflammatory response to early viral infection is associated to secretion of RANTES, a CC chemokine with chemotactic function which recruits circulating T cells to the inflammation sites. RANTES has been shown to be induced by several viral infections in a number of cell types, including the endothelial cell infection by HCMV ; in liver cells infected by dengue-2 virus , and in influenza A virus infection in monocyte/macrophages . In tumors, a dual role of RANTES has been reported  since it may promote tumor progression, as in melanomas , or the spreading of tumor cells throughout the body, as in breast cancer ; but RANTES may also enhance immune response against tumors and associate to improved prognosis as in the case of lung cancer .
A possible role for RANTES/CCR5 pathways in the pathogenesis of chronic HCV infection has been suggested from studies on HCV patients. Polymorphism of RANTES promoter was reported to correlate with outcome of HCV associated disease [12, 13], and individuals homozygous for deletion mutation of RANTES receptor (CCR5) showed increased susceptibility to chronic HCV infection . Lichterfeld and co-workers  reported that T cells from HCV patients had reduced responsiveness to RANTES. In addition, intra-hepatic expression of RANTES and Mig is positively related to the severity of hepatic inflammation , and intra-hepatic levels of RANTES mRNA have been reported to increase in chronic HCV patients . Modulation of RANTES expression in response to HCV has been somewhat controversial. In vitro studies have shown that full length HCV construct induces RANTES and MCP-1 expression in Huh7 and HeLa cells. On the other hand, inhibition of RANTES promoter in Huh7 and HepG2 cell lines has also been reported to be mediated by HCV core protein [18, 19]. More recently interaction of HCV E2 protein and CD81 has been suggested to lead to increased RANTES secretion by CD8 + lymphocytes [15, 20].
HCV core protein has been described as a multifunctional protein that in addition to function in viral nucleocapsid formation, influences several cellular function, such as cell growth and death [21–23], immune cells functions [24, 25] and its expression in transgenic mice has been associated to development of steatosis and hepatocellular carcinoma [26, 27]. Induction of chemokines by viral infection determines the local inflammation response and may be part of the virus induced pathogenicity. Modulation of chemokines expression by viruses or viral proteins may contribute to evasion of the innate immune response in early viral infection, affecting the outcome of infection and viral persistence.
RANTES activation by viral infection has been reported to be regulated by synergistic activity between interferon response factors, IRF-3, IRF-7 and NF-kB in various cell lines  and by IRF-1, which can bind to RANTES promoter in mouse macrophages . Moreover, HCV genome has been reported to modulate IRF-1 and IRF-7 in replicon system [30, 31].
NF90 belongs to a family of double-stranded-RNA binding proteins , which has been reported to regulate replication of the Pestivirus BVDV  (phylogenetically related to the Flavivirus family to which HCV belongs) and when introduced into osteosarcoma cell line it induces resistance to HIV replication in cell culture  acting as a component of cell defense against viral infection by activation of some IFN-response genes .
We examined the effect of HCV core and structural proteins on the expression of RANTES in human hepatoma and in a liver derived cell lines (HepG2 and Chang Liver) expressing different constructs of HCV genome. The expression of IRF-1 and IRF-7 has been examined to reveal their possible role in RANTES modulation by the core protein. In addition, we investigated the role of NF90 transfection on the expression of RANTES in order to reveal its possible immunomodulatory function and its potential to counteract HCV core protein effect on RANTES.
Stable transfectants and expression constructs
Stable transfectants in HepG2 cell lines expressing core and HCV structural proteins have been described by Harada et al., 1995 . Stable transfectants of Chang Liver (CHL) cell lines expressing HCV core (CH39) or core-E1-E2-NS2-NS3 (CH352) were established by stable transfection of Chang Liver cells with pCAG39neo, pCAG352neo expression vectors respectively, that expressed HCV structural and non-structural proteins under the control of mammalian CAG promoter. Clonal selection of liver cell transfectants was performed in the presence of 1 mg/ml of G418 antibiotic. Expression levels of HCV proteins were monitored by Western blotting. Positive clones were cultured and maintained under G418 selection; however experiments were performed in G418-free medium to avoid the possible influence of the antibiotic on functions under study as well as to maintain homologous conditions with the parental and control cell lines. Experimental control cell lines, Hepswx and CHwt were transfected with the empty vectors, pcEF321swxneo, described elsewhere by Harada et al.  and pcCAGswxneo. This latter plasmid obtained by inserting the CAG promoter cassette in pEF321neo vector linearized by Asp718 digestion; is a derivative of pCAGGS , containing the unique Swa I cloning site.
The pCI-NF90 construct (courtesy of Prof. Kumar A, George Washington University) containing the NF90 sequence under the control of CMV promoter has been described . Transfection of the established HepG2 and CHL cell lines with pCI-NF90 was performed by using Fugene 6 (Roche) according to manufacturer's instructions and with Fugene 6/plasmid DNA ratio of 3:1.
Immunofluorescence and FACS analysis
Detection and quantitation of RANTES protein expression in parental and transfected cell lines was performed by intracellular immunofluorescence and FACS analysis. Briefly, sub-confluent cultures were detached with trypsin-EDTA solution and washed in PBS. After fixation for 20 minutes at room temperature in 4% paraformaldehyde and washing with permeabilization solution (Perm/Wash Buffer, Becton Dickinson), 106 cells were suspended in 0.5 μg of mouse anti-human RANTES phycoerythrin-conjugated monoclonal antibody in Perm/Wash Buffer and were incubated for 15 minutes at room temperature. After washing in Perm/Wash Buffer cells were analysed by FACScalibur flow cytometer using CellQuest software. A minimum of 10,000 events were analysed for each sample.
RNA isolation and semiquantitative RT-PCR analysis
To detect RANTES mRNA, total RNA was extracted from cultured cell lines by RNeasy kit (Qiagen) according to manufacturer's instructions. 500 ng of total RNA was reverse transcribed using random hexanucleotides and 10 U of transcriptor™ reverse transcriptase (Roche) according to manufacturer's instructions with minor modifications and with the addition of recombinant RNAsin ribonuclease inhibitor. The PCR amplification of the reverse transcribed RNA was carried out with 1.5 unit of Taq DNA polimerase (ABI Prism) in 50 μl reaction mixture containing 200 μM of each dNTPs, 5 mM MgCl2, 20 μM of specific primers and 1× reaction buffer. Primers used for RANTES mRNA amplification in HepG2 cell lines were 5'-GCTGTCATCCTCATTGCTAC-3' (sense) and 5'-TCCATCCTAGCTCATCTCCA-3' (antisense), which yield a specific 260 (237) bp product; cycling conditions for HepG2 transfected cell lines were 94°C, 5 minutes, 56°C, 90 seconds and 72°C, 120 seconds, followed by 28 cycles at 94°C, 30 seconds, 56°C for 90 seconds and at 72°C for 120 seconds. Primers used to amplify RANTES from Chang Liver cell lines were: 5'-ACGCCTCGTGTCATCCTCATT-3' (sense) and 5'-ACTCTCCATCCTAGCTCATCTC-3' (antisense), which amplify a (226) bp product. PCR conditions were same as those described for HepG2 except MgCl2 concentration reduced to 1.5 mM and primers concentration to 0.1 μM. Cycling conditions were modified as follows: 94°C 4 minutes, 94°C 1 minute, 55°C 1 minute, 72°C 1 minute, for 40 cycles followed by 72°C 8 minutes. β-actin amplification in parallel samples was performed as controls by using following primers: 5'-ATCTGGCACCACACTTCTACA-3' (sense) and 5'-GTTTCGTGGATGCCAACAGGACT-3' (antisense) (550 bp product). Cycling conditions for β-actin were 94°C 4 minutes, 94°C 1 minute, 50°C 1 minute, 72°C 1 minute, followed by elongation at 72°C 8 minutes. In each experiment, possible DNA contamination was determined by a control reaction in which reverse transcriptase was omitted from the reaction mixture. For semi-quantitative RT-PCR analysis of RANTES, serial dilution of the cDNA samples was used. Amplified PCR fragments were analysed by electrophoresis in a 2% agarose gel.
Real-Time quantitative PCR analysis
Real-Time quantitative PCR assessment of RANTES gene expression in Hep39 cell lines was performed using the ABI PRISM 7000 Sequence Detector system (Applied Biosystem). 800 nanograms (ng) of total RNA were in vitro reverse transcribed as described above for RT-PCR analysis. A portion of the resulting cDNA corresponding to 80 ng of in vitro transcribed RNA was subjected to Real-Time quantitative PCR that was performed in triplicate using TaqMan chemistry with primers and probe sets from the Assay-on-Demand list (Applied Biosystem). The standard curve of the target RANTES gene was compared to the standard curve of β-microglobulin gene used as endogenous control reference; calculation of the slope of the log (ng RNA) vs ΔCt was always <0.1. Fold reduction was then calculated by the ΔΔCt method after normalization of the mRNA level to the values of β-microglobulin.
Transient transfection and luciferase reporter assay
2.5 μg of human RANTES reporter construct, pRANTES-Luc, (courtesy of Dr. Michael Gale), was transiently transfected by Fugene6 (Roche) in HepG2 and Chang Liver cell lines constitutively expressing HCV core protein, as well as in parental and the empty vector transfected control cells. To examine the effect of NF90 on RANTES activity 2.5 μg of the pCI-NF90 plasmid DNA was co-transfected with pRANTES-Luc into the liver cell lines. As transfection control, pSV β-galactosidase vector (1.0 μg) was co-transfected into the cells to monitor transfection efficiency. 48 h post-transfection, cell lysate was prepared and luciferase quantifications were performed using commercial reagents (Promega) and measuring in a Lumat LB 9501 Berthold Luminometer. Results are expressed as relative light units (RLU), calculated as the ratio of luciferase to β-galactosidase activities within each sample.
SDS-PAGE and immunoblotting analysis of IRF-1 and IRF-7
Total proteins (50 μg) were diluted in 2× sample buffer, separated by 10% SDS-PAGE and transferred onto PVDF membranes. After incubation in blocking buffer containing 5% milk, membranes were incubated overnight at 4°C with specific polyclonal antibodies anti-IRF-1 or IRF-7 (Santa Cruz). The membranes were subsequently incubated with HRP-conjugated anti-rabbit IgGs and immunodetection was realized by ECL (Pierce) followed by autoradiography.
The Student's t test and Fisher's exact test were used for comparison of the difference in RANTES expression between Hep39 and CH39 and their relative controls Hepswx and CHWT as well as to compare the luciferase activity of RANTES promoter in the two cell lines expressing HCV core protein. Differences were considered significant when p values were <0.05. Statistical analyses were performed using SPSS software (SPSS Inc).
Effect of HCV core protein on RANTES protein
Analysis of HCV on RANTES mRNA
Effect of HCV core protein on RANTES promoter
These results are consistent with the effect of HCV core protein on RANTES mRNA levels and suggest that the core protein regulates RANTES expression by influencing its promoter activity.
IRF-1 and IRF-7 expression in HepG2 and Chang liver cell lines
These results suggest that stable expression of HCV core protein induces IRF-1 expression in human hepatoblastoma cell line. Differential basal expression of IRF-1 between HepG2 and Chang Liver cell could be, at least in part, responsible for differential modulation of RANTES.
Results described in this study indicate that HCV core protein can either induce or inhibit RANTES chemokine expression in cell lines, depending on the cell type, arguing that RANTES promoter activity may be differentially regulated based on the availability of cell type specific transcription factors. Recruitment of virus-specific T cells to the liver is a critical step for HCV clearance. Chemokines such as RANTES, play a pivotal role in this process since they mediate lymphocytes migration. In addition, it has been reported , that RANTES/CCR5 expression is important in regulating relevant pathological events in the course of chronic hepatitis C infection; as well, intrahepatic expression of RANTES is positively related to the severity of hepatic inflammation in chronic hepatitis C. These results highlighted the significant role of this chemokine in HCV-induced liver disease. Consistent with recently reported observation , we found that HCV core protein variously modulated RANTES expression, by inducing its promoter. As discussed in the present study, opposite effects of HCV core protein on RANTES expression correlates with the different origin of the cell lines. HepG2 which is a human hepatoblastoma cell line with biochemical properties similar to hepatocytes, and Chang Liver cells are non-transformed human fibroblasts of liver origin. Immunohistochemical studies in vivo have indicated that RANTES and IP-10 chemokines are expressed in hepatocytes and that RANTES secretion increased in chronic hepatitis with a positive correlation to histological index of HCV related liver disease . Similar to other cancers (ovary and colorectal tumors) chemokines, which contribute to lymphocyte recruitment at tumor sites and to immune-mediated attack  have been reported to be secreted by hepatocellular carcinoma (HCC) as well. Interestingly, it has been reported that a mammary murine carcinoma cell line expressing low levels of RANTES showed a decreased growth rate in vivo . The reported evidences so far have pointed to a possible dual role of tumor-derived RANTES in tumor growth suggesting that inhibition of chemokine secretion by tumors could be a mechanism to evade immune attack. HepG2 cell line, a human hepatoblastoma cell line with hepatocytes characteristics, has been extensively investigated for the mechanisms of hepatocarcinogenesis; with regard to RANTES secretion HepG2 cell line behaves as tumor cells, whereas Chang Liver cells, a fibroblast-like cell line that is immortalized but without tumor phenotype, behave as non tumor cells with regard to the RANTES expression. The regulation of RANTES promoter by HCV proteins in these two liver cell types most likely reflects the available levels of the required transcription factors in these cell lines. The difference in the effects of HCV proteins on RANTES promoter is not due to their cellular localization, since the core protein is expressed in the cytoplasm of both HepG2 and the Chang Liver cells (data not shown). Since both the Hep39 and CH39 cell lines we utilized in the present study express full length (p21) HCV core protein, our data exclude the possibility that a truncated form of HCV core protein, which could migrate to the nucleus and affect NFk-B pathway (known to regulate expression of RANTES), could have influenced the results.
The effects of HCV envelope proteins on RANTES secretion are multifaceted. Recently, Soo et al. demonstrated that the intracellular co-expression of structural proteins E1-E2 suppress the HCV core-mediated activation of RANTES promoter reporter constructs in HeLa cells . In contrast, extracellular binding of HCV E2 to CD81 has been shown to increase RANTES secretion . We found, that co-expression of the core protein with E1-E2 and non-structural NS2-NS3 proteins of HCV counteracts the effect of HCV core expressed alone with respect to RANTES expression in both cellular systems. Thus, in line with Soo and colleagues, our results suggest that E1-E2 proteins counteract the effect of HCV core protein on RANTES expression, possibly by direct interaction of E1-E2 with the core protein in the cytoplasm. However, the role of the non-strucutral proteins NS2 and NS3 remains to be clarified in this context.
Expression of RANTES promoter has been reported to be regulated by IRF-3 and -7 cooperatively with NF-kB in U937 and in human kidney 293 cell lines as well as, in mouse macrophages, by IRF-1 which can bind to RANTES promoter [28, 37]. The HCV core protein expression in Huh7 and HeLa cell lines is able to induce IRF-1 mRNA but it does not influence IRF-3 expression and phosphorylation [, personal unpublished observations]. Consistent with the data from Miller and co-workers  we found that HCV core protein induces expression of IRF-1 in human hepatoblastoma cell lines (HepG2), but not in human fibroblast of liver origin (CHL, where IRF-1 is slightly expressed in parental cells). We suggest that the available level and different basal expression of IRF-1 between HepG2 and CHL cell lines could explain, at least in part, the opposite effect of HCV core protein on RANTES induction in the two cell lines examined.
NF90ctv is a nuclear transcription factor belonging to double-stranded RNA (dsRNA)-binding proteins , which is involved in the life cycle of bovine diarrhea virus (BVDV)  and can activate interferon response genes and inhibit HIV-1 replication . Interestingly, results obtained from present study indicated that NF90 protein has the ability to counter the effect of HCV core protein mediated RANTES expression in both cell types examined, suggesting its ability to counter virus mediated effect on host cell antiviral response. The mechanisms underlying its role are under investigation.
HCV core protein have opposite effects on the expression of RANTES in different cell types in vitro, possibly reflecting a similar scenario in different microenvironments in vivo.
Based on the data presented here we speculate that cell type specific factors play a fundamental role in RANTES expression. It is conceivable that core protein, which is expressed early in HCV infection in vivo and whose expression is maintained during chronic phase and in HCC cells, may have the opposite effects, influencing T cell trafficking in the liver through either the inhibition/induction of RANTES. Our data suggest a role, that needs to be confirmed in vivo for viral (HCV) proteins in contributing to immune evasion by tumor cells.
The authors gratefully acknowledge Dr. E. Stellacci for providing anti-IRF1, anti-IRF-7 antibodies and positive controls for immunoblotting and to Dr. A. Battistini for helpful discussion; Dr. T. Miyamura, Y. Matsuura and T. Harada for providing anti-HCV core, E1 and E2 monoclonal antibodies, constructs for transfection and for precious suggestions and discussion; S. Tocchio and R. Tomasetto for editorial and secretarial assistance; R. Gilardi for graphical assistance; Dr. E. Pozzi for statistical analysis. This work was performed as part of the IRCCS Ospedale Maggiore di Milano and Istituto Superiore di Sanità "Integrated National Project for the Study, the Prevention and the Treatment of the Chronic Hepatology" (no. H95, Experimental Models line) and it was also funded by the project of the Istituto Superiore di Sanità "Viral and Host Factors on Hepatitis Viruses Pathogenesis" (no. C3NC).
- Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J Clin. 2005, 55: 74-108.View ArticlePubMedGoogle Scholar
- El Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999, 340: 745-750. 10.1056/NEJM199903113401001.View ArticlePubMedGoogle Scholar
- Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M: Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004, 126: 1005-1014. 10.1053/j.gastro.2003.12.049.View ArticlePubMedGoogle Scholar
- Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004, 127: S35-S50. 10.1053/j.gastro.2004.09.014.View ArticlePubMedGoogle Scholar
- Billstrom Schroeder M, Worthen GS: Viral regulation of RANTES expression during human cytomegalovirus infection of endothelial cells. J Virol. 2001, 75: 3383-3390. 10.1128/JVI.75.7.3383-3390.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin YL, Liu CC, Chuang JI, Lei HY, Yeh TM, Lin YS, Huang YH, Liu HS: Involvement of oxidative stress, NF-IL-6, and RANTES expression in dengue-2-virus-infected human liver cells. Virology. 2000, 276: 114-126. 10.1006/viro.2000.0524.View ArticlePubMedGoogle Scholar
- Kaufmann A, Salentin R, Meyer RG, Bussfeld D, Pauligk C, Fesq H, Hofmann P, Nain M, Gemsa D, Sprenger H: Defense against influenza A virus infection: essential role of the chemokine system. Immunobiology. 2001, 204: 603-613. 10.1078/0171-2985-00099.View ArticlePubMedGoogle Scholar
- Adler EP, Lemken CA, Katchen NS, Kurt RA: A dual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett. 2003, 90: 187-194. 10.1016/j.imlet.2003.09.013.View ArticlePubMedGoogle Scholar
- Payne AS, Cornelius LA: The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol. 2002, 118: 915-922. 10.1046/j.1523-1747.2002.01725.x.View ArticlePubMedGoogle Scholar
- Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A: The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of pro-malignant activity. Cancer Res. 2002, 62: 1093-1102.PubMedGoogle Scholar
- Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash S, Beer DG: RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res. 2002, 8: 3803-3812.PubMedGoogle Scholar
- Goulding C, Murphy A, MacDonald G, Barrett S, Crowe J, Hegarty J, McKiernan S, Kelleher D: The CCR5-Δ32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut. 2005, 54: 1157-1161. 10.1136/gut.2004.055699.View ArticlePubMedPubMed CentralGoogle Scholar
- Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P, Satsangi J, Wright M, Zhang L, Thomas HC, Thursz M, Hill AV: Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology. 2003, 38: 1468-1476.View ArticlePubMedGoogle Scholar
- Ahlenstiel G, Woitas RP, Rockstroh J, Spengler U: CC-chemokine receptor 5 (CCR5) in hepatitis C – at the crossroads of the antiviral immune response?. J Antimicrob Chemother. 2004, 53: 895-898. 10.1093/jac/dkh239.View ArticlePubMedGoogle Scholar
- Lichterfeld M, Leifeld L, Nischalke HD, Rockstroh JK, Hess L, Sauerbruch T, Spengler U: Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. J Infect Dis. 2002, 185: 1803-1807. 10.1086/340829.View ArticlePubMedGoogle Scholar
- Apolinario A, Majano PL, Alvarez-Pérez E, Saez A, Lozano C, Vargas J, Garcia-Monzòn C: Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol. 2002, 97: 2861-2870. 10.1111/j.1572-0241.2002.07054.x.View ArticlePubMedGoogle Scholar
- Nischalke HD, Nattremann J, Fischer HP, Sauerbruch T, Spengler U, Dumoulin FL: Semiquantitative analysis of intrahepatic CC-chemokine mRNas in chronic hepatitis C. Mediators Inflamm. 2004, 13: 357-359. 10.1080/09629350400003159.View ArticlePubMedPubMed CentralGoogle Scholar
- Soo HM, Garzino-Demo A, Hong W, Tan YH, Tan YJ, Goh P-Y, Lim SG, Lim SP: Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES. Virology. 2002, 303: 253-277. 10.1006/viro.2002.1617.View ArticlePubMedGoogle Scholar
- Apolinario A, Majano PL, Lorente R, Nunez O, Clemente G, Garcia-Monzon C: Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins. J Viral Hepatol. 2005, 12: 27-37. 10.1111/j.1365-2893.2005.00540.x.View ArticleGoogle Scholar
- Nattermann J, Nischalke HD, Feldmann G, Ahlenstiel G, Sauerbruch T, Spengler U: Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5. J Viral Hepatol. 2004, 11: 519-526. 10.1111/j.1365-2893.2004.00545.x.View ArticleGoogle Scholar
- Fukutomi T, Zhou Y, Kawai S, Eguchi H, Wands JR, Li J: Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology. 2005, 41: 1096-1105. 10.1002/hep.20668.View ArticlePubMedGoogle Scholar
- Realdon S, Gerotto M, Dal Pero F, Marin O, Granato A, Basso G, Muraca M, Alberti A: Proapoptotic effect of hepatitis C virus CORE protein in transiently transfected cells is enhanced by nuclear localization and is dependent on PKR activation. J Hepatol. 2004, 40: 77-85. 10.1016/j.jhep.2003.09.017.View ArticlePubMedGoogle Scholar
- Ruggieri A, Harada T, Matsuura Y, Miyamura T: Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology. 1997, 229: 68-76. 10.1006/viro.1996.8420.View ArticlePubMedGoogle Scholar
- Grakui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM: HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003, 302: 659-662. 10.1126/science.1088774.View ArticleGoogle Scholar
- Eisen-Vandervelde AL, Waggoner SN, Yao ZO, Cale EM, Hahn CS, Hahn YS: Hepatitis C virus core selectively suppresses IL-12synthesis in human macrophages by interfering with AP-1 activation. J Biol Chem. 2004, 279: 43479-43486. 10.1074/jbc.M407640200.View ArticlePubMedGoogle Scholar
- Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K: Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 1997, 78: 1527-1531.View ArticlePubMedGoogle Scholar
- Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998, 4: 1065-1067. 10.1038/2053.View ArticlePubMedGoogle Scholar
- Genin P, Algartè M, Roof P, Lin R, Hiscott J: Regulation of RANTES chemokine gene expression requires cooperativity between NF-kB and IFN-regulatory factor transcription factors. J Immunol. 2000, 164: 5352-5361.View ArticlePubMedGoogle Scholar
- Miller K, McArdle S, Gale MJ, Geller DA, Tenoever B, Hiscott J, Gretch DR, Polyak SJ: Effect of the hepatitis C virus core protein on innate cellular defense pathways. J Interferon Citokine Res. 2004, 24: 391-402. 10.1089/1079990041535647.View ArticleGoogle Scholar
- Kanazawa N, Kurosaki M, Sakamoto N, Enomoto N, Itsui Y, Yamashiro T, Tanabe Y, Maekawa S, Nakagawa M, Chen CH, Kakinuma S, Oshima S, Nakamura T, Kato T, Wakita T, Watanabe M: Regulation of hepatitis C virus replication by interferon regulatory factor 1. J Virol. 2004, 78: 9713-9720. 10.1128/JVI.78.18.9713-9720.2004.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang T, Lin RT, Li Y, Douglas SD, Maxcey C, Ho C, Lai JP, Wang YJ, Wan Q, Ho WZ: Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology. 2005, 42: 819-827. 10.1002/hep.20854.View ArticlePubMedGoogle Scholar
- Reichman TW, Muniz LC, Mathews MB: The RNA binding protein nuclear factor 90 functions as both a positive and negative regulator of gene expression in mammalian cells. Mol Cell Biol. 2002, 22: 343-356. 10.1128/MCB.22.1.343-356.2002.View ArticlePubMedPubMed CentralGoogle Scholar
- Isken O, Grassmann CW, Sarisky RT, Kann M, Zhang S, Grosse F, Kao PN, Behrens SE: Members of the NF90/NFAR protein group are involved in the life cycle of a positive-strand RNA virus. EMBO J. 2003, 22: 5655-5665. 10.1093/emboj/cdg562.View ArticlePubMedPubMed CentralGoogle Scholar
- Krasnoselskaya-Riz I, Spruill A, Chen YW, Schuster D, Teslovich T, Baker C, Kumar A, Stephan DA: Nuclear Factor 90 mediates activation of the cellular antiviral expression cascade. AIDS Res Hum Retroviruses. 2002, 18: 591-604. 10.1089/088922202753747941.View ArticlePubMedGoogle Scholar
- Harada T, Kim DW, Sagawa K, Suzuki T, Takahashi K, Saito I, Matsuura Y, Miyamura T: Characterization of an established human hepatoma cell line constitutively expressing non-structural proteins of hepatitis C virus by transfection of viral cDNA. J Gen Virol. 1995, 76: 1215-1221.View ArticlePubMedGoogle Scholar
- Niwa H, Yamamura K, Miyazaki J: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991, 108: 193-199. 10.1016/0378-1119(91)90434-D.View ArticlePubMedGoogle Scholar
- Liu J, Guan X, Ma X: Interferon regulatory factor 1 is an essential and indirect transcriptional activator for IFNγ-induced RANTES/CCL5 expression in macrophages. J Biol Chem. 2005, 280: 24347-24355. 10.1074/jbc.M500973200.View ArticlePubMedGoogle Scholar
- Yoong KF, Afford SC, Jones R, Aujla P, Qin S, Price K, Hubscher SG, Adams DH: Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology. 1999, 30: 100-111. 10.1002/hep.510300147.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/7/21/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.